Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Human Papillomavirus (HPV) Vaccine Market: By Type: Bivalent, Polyvalent; By Distribution Channel: Hospital and Retail Pharmacies, Government Suppliers, Others; By Indication; By Diseases; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Human Papillomavirus (HPV) Vaccine Market Outlook
The global human papillomavirus (HPV) vaccine market attained a value of nearly USD 4.2 billion in 2021. The market is estimated to grow in the forecast period of 2023-2028 at a CAGR of 11.50% to reach about USD 8.1 billion by 2027.
North America to Hold a Significant Share in the Market for Human Papillomavirus (HPV) Vaccine
The human papillomavirus (HPV) vaccine market in North America is expected to witness significant growth during the forecast period on account of the increasing awareness regarding human papillomavirus among the masses and the surging association of human papillomavirus with cervical cancer. The increasing incidences of human papillomavirus (HPV) associated cancers and the rising focus to prevent these infections are further driving the market growth of human papillomavirus (HPV) vaccine. Moreover, the developing healthcare infrastructure and the growing healthcare expenditure in developing countries are likely to create healthy growth opportunities for the market players in the region. In the United States, human papillomavirus is one of the most common sexually transmitted infections, which is likely to propel the market for HPV vaccine over the forecast period.
Market Segmentation
Human papillomavirus (HPV) vaccine is a vaccination that is typically administered in children at age 11-12 years and protects them from certain cancers. It also prevents vaginal and vulvar cancer. Additionally, the vaccine can prevent anal cancers, genital warts, and mouth, throat, neck, and head cancers in men and women. Gardasil 9 is an HPV vaccine approved by the U.S. Food and Drug Administration and can be used for both females and males.
The market for human papillomavirus (HPV) vaccine, by type, is divided into:
- Bivalent
- Polyvalent
The market can be broadly categorised on the basis of distribution channel segments into:
- Hospital and Retail Pharmacies
- Government Suppliers
- Others
Based on Indication, the market is segmented into:
- Genital Warts
- HPV Associated Cancer
By diseases, the market is segmented into:
- Systemic Human Papillomavirus Vaccine
- Systemic Lupus Erythematosus
- Ankylosing Spondylitis
- Rheumatoid Arthritis
- Others
- Localised Human Papillomavirus Vaccine
- Inflammatory Bowel Disease
- Type 1 Diabetes
- Thyroid
- Others
The EMR report looks into the regional markets of human papillomavirus (HPV) vaccine like Latin America, North America, Europe, the Asia Pacific, and the Middle East and Africa.
Growing Cases of Human Papillomavirus (HPV) to Fuel the Market Growth of Human Papillomavirus (HPV) Vaccine
The human papillomavirus (HPV) vaccine market is likely to witness growth during the forecast period on account of the rising cases of human papillomavirus diseases. The surging initiatives by organisations and governments for early screening and vaccination of HPV, coupled with the emergence of new HPV vaccines like Gardasil 9, are expected to drive the market growth of human papillomavirus (HPV) vaccine. The growing incidences of HPV-related malignancies in the oropharynx, anal, and genital areas, coupled with an upsurge in demand for HPV vaccinations to help reduce infections, are expected to bolster the market for human papillomavirus (HPV) vaccine. The increasing R&D activities to prevent and control the spread of such diseases through preventative immunisations are further expected to fuel the market for the human papillomavirus (HPV) vaccine.
Key Players in the Global Market for Human Papillomavirus (HPV) Vaccine
The report presents a detailed analysis of the following key players in the global human papillomavirus (HPV) vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Johnson & Johnson Services, Inc.
- Serum Institute of India Pvt. Ltd.
- Bavarian Nordic A/S
- Others
The comprehensive report looks into the macro and micro aspects of the market. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Indication |
|
| Breakup by Diseases |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Application
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Human Papillomavirus (HPV) Vaccine Market Analysis
8.1 Key Industry Highlights
8.2 Global Human Papillomavirus (HPV) Vaccine Historical Market (2018-2022)
8.3 Global Human Papillomavirus (HPV) Vaccine Market Forecast (2023-2028)
8.4 Global Human Papillomavirus (HPV) Vaccine Market by Type
8.4.1 Bivalent
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Polyvalent
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.5 Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
8.5.1 Hospital and Retail Pharmacies
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Government Suppliers
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Others
8.6 Global Human Papillomavirus (HPV) Vaccine Market by Indication
8.6.1 Genital Warts
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 HPV Associated Cancer
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.7 Global Human Papillomavirus (HPV) Vaccine Market by Diseases
8.7.1 Systemic Human Papillomavirus Vaccine
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2022)
8.7.1.3 Forecast Trend (2023-2028)
8.7.1.4 Breakup by Type
8.7.1.4.1 Systemic Lupus Erythematosus
8.7.1.4.2 Ankylosing Spondylitis
8.7.1.4.3 Rheumatoid Arthritis
8.7.1.4.4 Others
8.7.2 Localised Human Papillomavirus Vaccine
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2022)
8.7.2.3 Forecast Trend (2023-2028)
8.7.2.4 Breakup by Type
8.7.2.4.1 Inflammatory Bowel Disease
8.7.2.4.2 Type 1 Diabetes
8.7.2.4.3 Thyroid
8.7.2.4.4 Others
8.8 Global Human Papillomavirus (HPV) Vaccine Market by Region
8.8.1 Market Share
8.8.1.1 North America
8.8.1.2 Europe
8.8.1.3 Asia Pacific
8.8.1.4 Latin America
8.8.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Company Profiles
13.2.1 Merck & Co., Inc.
13.2.1.1 Company Overview
13.2.1.2 Product Portfolio
13.2.1.3 Demographic Reach and Achievements
13.2.1.4 Certifications
13.2.2 GlaxoSmithKline plc.
13.2.2.1 Company Overview
13.2.2.2 Product Portfolio
13.2.2.3 Demographic Reach and Achievements
13.2.2.4 Certifications
13.2.3 Johnson & Johnson Services, Inc.
13.2.3.1 Company Overview
13.2.3.2 Product Portfolio
13.2.3.3 Demographic Reach and Achievements
13.2.3.4 Certifications
13.2.4 Serum Institute of India Pvt. Ltd.
13.2.4.1 Company Overview
13.2.4.2 Product Portfolio
13.2.4.3 Demographic Reach and Achievements
13.2.4.4 Certifications
13.2.5 Bavarian Nordic A/S
13.2.5.1 Company Overview
13.2.5.2 Product Portfolio
13.2.5.3 Demographic Reach and Achievements
13.2.5.4 Certifications
13.2.6 Others
14 Industry Events and Developments
List of Key Figures and Tables
1. Global Human Papillomavirus (HPV) Vaccine Market: Key Industry Highlights, 2018 and 2028
2. Global Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Type (USD Million), 2018-2022
3. Global Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Type (USD Million), 2023-2028
4. Global Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Distribution Channel (USD Million), 2018-2022
5. Global Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Distribution Channel (USD Million), 2023-2028
6. Global Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Indication (USD Million), 2018-2022
7. Global Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Indication (USD Million), 2023-2028
8. Global Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Diseases (USD Million), 2018-2022
9. Global Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Diseases (USD Million), 2023-2028
10. Global Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Region (USD Million), 2018-2022
11. Global Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Region (USD Million), 2023-2028
12. North America Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Country (USD Million), 2018-2022
13. North America Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Europe Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Country (USD Million), 2018-2022
15. Europe Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Asia Pacific Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Country (USD Million), 2018-2022
17. Asia Pacific Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Latin America Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Country (USD Million), 2018-2022
19. Latin America Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Country (USD Million), 2023-2028
20. Middle East and Africa Human Papillomavirus (HPV) Vaccine Historical Market: Breakup by Country (USD Million), 2018-2022
21. Middle East and Africa Human Papillomavirus (HPV) Vaccine Market Forecast: Breakup by Country (USD Million), 2023-2028
22. North America Historical Price Trends and Forecast 2018-2028
23. Europe Historical Price Trends and Forecast 2018-2028
24. Asia Pacific Historical Price Trends and Forecast 2018-2028
25. Latin America Historical Price Trends and Forecast 2018-2028
26. Middle East and Africa Historical Price Trends and Forecast 2018-2028
27. Global Human Papillomavirus (HPV) Vaccine Market Structure
Key Questions Answered in the Report
In 2021, the global human papillomavirus (HPV) vaccine market attained a value of nearly USD 4.2 billion.
The market is assessed to grow at a CAGR of 11.50% between 2023 and 2028.
The market is estimated to witness healthy growth in the forecast period of 2023-2028 to reach almost USD 8.1 billion by 2027.
The major market drivers are the growing awareness regarding human papillomavirus, the rising incidences of HPV-associated cancers, the increasing healthcare facilities.
The key market trends guiding the growth of the market include the introduction of various government initiatives to boost HPV vaccination, the growing incidences of HPV-related malignancies, and developing healthcare infrastructure.
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The various types of human papillomavirus virus (HPV) vaccine in the market are bivalent and polyvalent.
The different distribution channel of human papillomavirus (HPV) vaccine include hospital and retail pharmacies and government suppliers, among others.
The significant indications of human papillomavirus (HPV) vaccine in the market are genital warts and HPV associated cancer.
The major diseases of human papillomavirus (HPV) vaccine, include systemic human papillomavirus vaccine and localised human papillomavirus vaccine.
The major players in the market are Merck & Co., Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Serum Institute of India Pvt. Ltd., and Bavarian Nordic A/S, among others.
Analyst Review
The global human papillomavirus (HPV) vaccine market attained a value of nearly USD 4.2 billion in 2021, driven by the increasing awareness about human papillomavirus. Aided by the growing demand for human papillomavirus (HPV) vaccines, the market is expected to witness further growth in the forecast period of 2023-2028, growing at a CAGR of 11.50%. The market is estimated to reach about USD 8.1 billion by 2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the market. The market for human papillomavirus (HPV) vaccine, by type, is divided into bivalent and polyvalent. On the basis of distribution channel, the market is segmented into hospital and retail pharmacies and government suppliers, among others. Based on indications, the market is bifurcated into genital warts and HPV associated cancer. On the basis of diseases, the market is classified into systemic human papillomavirus vaccine and localised human papillomavirus vaccine. The major regional markets for human papillomavirus (HPV) vaccine are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Merck & Co., Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Serum Institute of India Pvt. Ltd., and Bavarian Nordic A/S, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER